Incyte Co. (NASDAQ:INCY) Shares Acquired by Baker BROS. Advisors LP

Baker BROS. Advisors LP increased its holdings in shares of Incyte Co. (NASDAQ:INCY) by 0.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 30,739,020 shares of the biopharmaceutical company’s stock after acquiring an additional 496 shares during the period. Incyte accounts for about 21.1% of Baker BROS. Advisors LP’s holdings, making the stock its 2nd biggest holding. Baker BROS. Advisors LP owned about 0.16% of Incyte worth $2,031,849,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in INCY. Atria Investments Inc acquired a new stake in Incyte in the 1st quarter worth about $1,056,000. Cetera Advisors LLC acquired a new stake in shares of Incyte in the first quarter worth approximately $241,000. DekaBank Deutsche Girozentrale increased its position in shares of Incyte by 19.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 152,452 shares of the biopharmaceutical company’s stock worth $8,652,000 after purchasing an additional 24,328 shares in the last quarter. GAMMA Investing LLC raised its stake in Incyte by 38.2% in the 2nd quarter. GAMMA Investing LLC now owns 2,864 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 791 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in Incyte by 34.4% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 1,009 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 258 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Analyst Upgrades and Downgrades

INCY has been the topic of several research reports. Royal Bank of Canada raised their price target on shares of Incyte from $72.00 to $80.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 14th. William Blair restated an “outperform” rating on shares of Incyte in a research report on Monday, September 9th. Bank of America raised Incyte from a “neutral” rating to a “buy” rating and increased their price target for the company from $68.00 to $90.00 in a report on Tuesday, October 29th. Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research note on Tuesday, November 19th. Finally, The Goldman Sachs Group raised their target price on Incyte from $63.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Incyte has an average rating of “Hold” and an average target price of $77.16.

Incyte Stock Down 1.1 %

Incyte stock opened at $74.59 on Monday. The stock’s fifty day moving average is $70.76 and its two-hundred day moving average is $65.22. The stock has a market cap of $14.37 billion, a PE ratio of 532.82, a P/E/G ratio of 8.60 and a beta of 0.71. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.87 and a quick ratio of 1.82.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.12). The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. Incyte’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.91 EPS. On average, sell-side analysts expect that Incyte Co. will post 0.4 EPS for the current fiscal year.

Insider Transactions at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 3,680 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $79.68, for a total transaction of $293,222.40. Following the transaction, the executive vice president now owns 58,042 shares of the company’s stock, valued at approximately $4,624,786.56. This trade represents a 5.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Tray sold 572 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the completion of the sale, the insider now directly owns 24,825 shares of the company’s stock, valued at $1,562,485.50. The trade was a 2.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,702 shares of company stock worth $856,166. 17.60% of the stock is currently owned by insiders.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.